Psy96 - Cost-Effectiveness of Originator Adalimumab in Non-Infectious Intermediate, Posterior and Pan-Uveitis From a Societal Perspective in Portugal

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2671
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Cost-Effectiveness of Glycopyrronium Compared to Tiotropium in COPD Patients From a Swedish Societal Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Cost-Effectiveness of Ticagrelor 60 Mg in High-Risk Post-Mi Patients From a Dutch Societal Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

FRI0618 Adalimumab in Non-Infectious Uveitis – Efficacy Across Different Etiologies in the Visual I and Visual Ii Trials

2017English

Dexamethasone Implant for Non-Infectious Uveitis: Is It Cost-Effective?

British Journal of Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2019English

Cyclosporine vs Tacrolimus Therapy for Posterior and Intermediate Uveitis

Archives of Ophthalmology
2005English

SAT0590 Long-Term Efficacy and Safety of Adalimumab by Aetiologyin Patients With Non-Infectious Uveitis in the Visual Iii Trial

2018English

Electroretinogram Abnormalities in Non-Infectious Uveitis Often Persist

Acta Ophthalmologica
MedicineOphthalmology
2020English

Cost-Effectiveness of Adalimumab for Rheumatoid Arthritis in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Treatment of Chronic Non-Infectious Uveitis and Scleritis

Swiss Medical Weekly
Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy